Log in to your Inderes Free account to see all free content on this page.
Annexin Pharmaceuticals
13.15 SEK
+4.78 %
Less than 1K followers
ANNX
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Quarter data
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Annexin Pharmaceuticals
| Q3/24 | Q4/24 | 2024 | Q1/25 | Q2/25 | Q3/25 | Q4/25 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||
| EBITDA | -10.9 | -12.6 | -50.5 | -8.0 | -8.6 | -10.1 | ||
| EBIT | -10.9 | -12.6 | -50.5 | -8.0 | -8.6 | -10.1 | -10.8 | -37.4 |
| EBIT-% | ||||||||
| Profit before taxes | -10.9 | -12.4 | -50.3 | -8.0 | -8.5 | -9.9 | -10.5 | -36.9 |
| Net income | -10.9 | -12.4 | -50.3 | -8.0 | -8.5 | -9.9 | -10.5 | -36.9 |
Login required
This content is only available for logged in users